Biora Therapeutics, Inc. has filed a prospectus supplement on April 2, 2024, which updates and amends certain information from the original prospectus dated February 7, 2023. The supplement pertains to the resale offering of 90,000 shares of common stock, issuable upon the exercise of warrants. The company has entered into a Warrant Amendment Agreement with an institutional investor to amend the exercise price of the warrants from $8.22 to $1.10 per share. Additionally, the amended warrants will not be exercisable until Biora Therapeutics receives stockholder approval for the issuance of shares upon exercise of the warrants, and the expiration date of the warrants has been extended to five years post-approval. The amendments took effect on March 31, 2024, and the last reported sale price of Biora Therapeutics' common stock on the Nasdaq Global Market was $1.10 per share as of March 28, 2024.

Biora Therapeutics, Inc. has filed a prospectus supplement on April 2, 2024, which updates and amends certain information from the original prospectus dated February 7, 2023. The supplement pertains to the resale offering of 90,000 shares of common stock, issuable upon the exercise of warrants. The company has entered into a Warrant Amendment Agreement with an institutional investor to amend the exercise price of the warrants from $8.22 to $1.10 per share. Additionally, the amended warrants will not be exercisable until Biora Therapeutics receives stockholder approval for the issuance of shares upon exercise of the warrants, and the expiration date of the warrants has been extended to five years post-approval. The amendments took effect on March 31, 2024, and the last reported sale price of Biora Therapeutics' common stock on the Nasdaq Global Market was $1.10 per share as of March 28, 2024.